Armour Thyroid: How to Safely Stop

What Is Armour Thyroid and How Does It Work?

Armour Thyroid is a prescription tablet made from desiccated porcine thyroid glands. Each 60 mg grain contains approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3), plus thyroglobulin, calcitonin, and other native thyroid proteins. Because it delivers both active hormones simultaneously, its mechanism differs meaningfully from synthetic levothyroxine monotherapy.

The T4/T3 Dual-Hormone Mechanism

T4 is a prohormone. After absorption, peripheral tissues convert it to the biologically active T3 via deiodinase enzymes. T3 then binds thyroid hormone receptors in the nucleus, regulating gene transcription for metabolism, cardiac output, thermogenesis, and neurological function. Armour Thyroid skips part of that conversion step by supplying T3 directly.

This has a practical consequence for tapering: the T3 component clears the body in one to two days, while T4 has a half-life of six to seven days. Patients who stop NDT abruptly may notice T3-withdrawal symptoms (fatigue, brain fog, cold sensitivity) within 48 to 72 hours, well before TSH begins to climb.

Why the Porcine Ratio Matters

The T4:T3 ratio in porcine thyroid (approximately 4.2:1 by mass) is higher in T3 than the human thyroid produces (roughly 14:1 in secretion). This means NDT delivers a supraphysiologic T3 pulse relative to normal human thyroid output. The FDA-approved labeling for Armour Thyroid notes this discrepancy, and the 2014 American Thyroid Association (ATA) guidelines acknowledge it as one reason some clinicians prefer levothyroxine monotherapy for long-term management. [1][2]

How Armour Thyroid Affects TSH Suppression

Because T3 is more potent than T4 at suppressing pituitary TSH release, patients taking NDT often show lower or even suppressed TSH values compared to levothyroxine patients at equivalent metabolic effect. A 2013 randomized crossover trial by Hoang et al. (J Clin Endocrinol Metab, N=70) found TSH was similarly controlled on NDT versus levothyroxine, but free T3 levels were higher on NDT and free T4 levels were lower. [3] Understanding this TSH dynamic is essential before designing a stop protocol, because a "normal" TSH on NDT may not indicate the same thyroid reserve as a normal TSH on levothyroxine.

Why Patients Stop Armour Thyroid

Patients and clinicians consider discontinuing NDT for several distinct reasons, each of which affects the appropriate stopping strategy.

Transient or Resolving Hypothyroidism

Some hypothyroid states are temporary. Postpartum thyroiditis resolves in 40 to 80% of affected women within 12 to 18 months. [4] Subacute (de Quervain) thyroiditis typically restores euthyroid function within two to four months of the acute phase. In these patients, the clinical goal is a monitored wean, not permanent replacement.

Switching to Levothyroxine

The most common reason for stopping Armour Thyroid is converting to synthetic T4. Reasons include formulary constraints, supply shortages (NDT has experienced national shortage periods), pregnancy (where stable T4 dosing is preferred), or physician preference aligned with ATA guidelines. [2] A direct-conversion approach rather than a true discontinuation is standard here, covered in detail below.

Patient-Initiated Stopping

Some patients stop NDT because of perceived side effects: palpitations, anxiety, or insomnia, which are consistent with excess T3 exposure. Others stop during a period of medication non-compliance. Abrupt self-discontinuation without physician guidance is common and carries real risk.

Thyroid Cancer Follow-Up or Ablation

Patients who had thyroid cancer and were on NDT post-thyroidectomy may need to stop NDT entirely before radioactive iodine (RAI) ablation or diagnostic scanning, to allow TSH to rise above 30 mIU/L. In this setting, abrupt discontinuation is intentional and medically directed.

The Physiology Behind Stopping: What Happens After the Last Dose

When Armour Thyroid is stopped, two hormones clear at different rates.

The T3 fraction (half-life 1 to 2 days) falls rapidly. By day four to five, circulating T3 is near baseline and symptoms may emerge. The T4 fraction (half-life 6 to 7 days) falls more slowly. TSH, which is suppressed by both hormones, begins rising in most patients by day 10 to 14 after the last dose. For patients who were TSH-suppressed on NDT, TSH may take three to four weeks to escape suppression entirely.

Full return to hypothyroid TSH levels (above 4.5 mIU/L in most lab reference ranges) typically occurs by four to six weeks after abrupt cessation in patients with primary hypothyroidism and absent or minimal residual thyroid function. [5]

The practical takeaway: a taper spread over four to eight weeks blunts the hormonal drop at each step, preventing the sharp T3 and T4 withdrawal that produces symptomatic hypothyroidism.

Step-by-Step Tapering Protocol

There is no FDA-approved tapering schedule for Armour Thyroid discontinuation. The protocol below is derived from thyroid physiology, the ATA 2014 guidelines, and clinical practice patterns reported in peer-reviewed endocrinology literature.

Step 1: Confirm the Indication for Stopping

Before reducing dose, a baseline TSH and free T4 should be drawn. If TSH is already elevated at baseline, the patient may already be undertreated, and stopping without a plan to transition to replacement therapy is medically inappropriate.

Document:

• Current NDT dose in grains and milligrams
• Most recent TSH (ideally within six weeks)
• Presence of symptoms: palpitations, anxiety (suggesting over-treatment) or fatigue, cold intolerance (suggesting under-treatment)
• Presence of residual thyroid tissue (Hashimoto's patients with some function vs. Post-thyroidectomy patients with zero endogenous output)

Step 2: Choose a Strategy

Strategy A: Straight taper to zero (for resolving hypothyroidism)

Reduce the daily dose by 25 to 30 mg (approximately half a grain) every two to four weeks. Check TSH four weeks after each reduction. If TSH remains below 4.5 mIU/L, proceed to the next reduction. If TSH rises above 4.5 mIU/L before the planned stop date, reassess whether full discontinuation is appropriate.

A patient on 2 grains (120 mg) daily might follow this schedule:

• Weeks 1 to 4: 90 mg/day (1.5 grains)
• Weeks 5 to 8: 60 mg/day (1 grain)
• Weeks 9 to 12: 30 mg/day (0.5 grain)
• Week 13: discontinue

Strategy B: Cross-taper to levothyroxine

Using the conversion of 1 grain NDT ≈ 100 mcg levothyroxine, start levothyroxine at the calculated dose on the same day NDT is reduced or stopped. Some clinicians prefer a one-week overlap at half-doses of each to prevent gaps.

A patient on 1.5 grains NDT (90 mg) would convert to approximately 150 mcg levothyroxine. Starting levothyroxine at 125 mcg with a plan to titrate after six weeks of TSH monitoring is a reasonable conservative approach.

Strategy C: Abrupt stop under medical supervision

Reserved for RAI preparation or acute toxicity (thyrotoxicosis from over-replacement). TSH is monitored at two and four weeks. Symptomatic support (beta-blocker for palpitations if stopping due to over-replacement) may be appropriate.

Step 3: Monitor TSH and Symptoms at Each Step

The ATA recommends TSH monitoring every four to eight weeks after any thyroid hormone dose change. [2] For a multi-step taper, check TSH:

• Four weeks after each dose reduction
• Four to six weeks after the final dose
• Three months after full discontinuation

Free T3 monitoring is not universally recommended by guidelines, but it can help distinguish between TSH suppression from exogenous T3 versus true euthyroidism in the early taper weeks.

Step 4: Recognize and Respond to Symptoms

Common hypothyroid symptoms to watch during taper:

• Fatigue and somnolence
• Cold intolerance
• Constipation
• Weight gain (typically 2 to 5 lb of fluid before tissue effects)
• Slowed heart rate (resting HR below 55 bpm)
• Brain fog or slowed cognition
• Dry skin or hair loss

If two or more of these symptoms emerge with a rising TSH, the taper pace should slow or a bridging dose should be reintroduced while the clinical picture is reassessed.

Special Populations Requiring Modified Protocols

Pregnancy

Thyroid hormone requirements increase by approximately 30 to 50% in the first trimester. [6] Stopping NDT during pregnancy without transitioning to adequate levothyroxine is contraindicated. The Endocrine Society's 2012 guidelines on thyroid disease in pregnancy recommend maintaining TSH below 2.5 mIU/L in the first trimester and below 3.0 mIU/L in the second and third trimesters. [6] NDT is generally switched to levothyroxine during pregnancy due to the more stable and predictable T4 pharmacokinetics.

Cardiovascular Disease

Patients with known coronary artery disease or a history of atrial fibrillation require slower tapering. Abrupt T3 withdrawal can paradoxically increase cardiac workload in some patients. A 12-week taper rather than the standard four to eight weeks is a reasonable precaution. A 2019 review in the Journal of Clinical Endocrinology and Metabolism noted that excess T3 exposure from NDT was associated with modestly elevated resting heart rate in crossover studies, and careful dose reduction is warranted in patients with arrhythmia risk. [7]

Post-Thyroidectomy Patients

Patients with total thyroidectomy produce no endogenous thyroid hormone. In these patients, any NDT discontinuation without equivalent replacement will produce overt hypothyroidism within two to four weeks. Strategy B (cross-taper to levothyroxine) is almost always appropriate. True discontinuation without replacement is medically appropriate only for RAI preparation, and only for the shortest feasible duration.

Hashimoto's Thyroiditis With Partial Function

Patients with Hashimoto's who retain some thyroid function have a partial buffer against rapid TSH elevation during taper. Their residual T4 secretion may slow the TSH rise. Nonetheless, anti-TPO antibody titers do not predict residual function reliably enough to forgo TSH monitoring.

Armour Thyroid vs. Levothyroxine: What the Evidence Shows

The Hoang et al. (2013) crossover trial remains the most cited head-to-head comparison. Seventy patients with hypothyroidism were randomized to NDT or levothyroxine for 16 weeks, then crossed over for another 16 weeks. TSH was equally controlled, but NDT patients had higher free T3 and lower free T4. Forty-nine percent of patients preferred NDT at the end of the study, 19% preferred levothyroxine, and 33% had no preference. [3] The authors concluded that NDT "did not result in worse outcomes" and that patient preference is a valid clinical consideration.

The ATA's 2014 hypothyroidism guidelines state: "There is insufficient evidence to recommend for or against the routine use of combination T4/T3 therapy" and note that patients who do not achieve well-being on levothyroxine monotherapy represent a population in whom combination therapy or NDT may be considered. [2]

A 2019 Cochrane-adjacent systematic review found no significant difference in quality of life between NDT and levothyroxine across four randomized trials, though all four trials were underpowered. [8] This evidence base supports the clinical stance that switching from NDT is not urgently required on efficacy grounds; it is a shared clinical decision.

Drug Interactions and Timing Considerations During the Taper

Several medications reduce NDT absorption and must be spaced at least four hours apart:

• Calcium carbonate and calcium citrate supplements
• Ferrous sulfate and other iron supplements
• Proton pump inhibitors (PPIs, e.g., omeprazole) reduce gastric acid and impair T4 absorption
• Cholestyramine and colestipol (bile acid sequestrants)
• Sucralfate
• Antacids containing magnesium or aluminum hydroxide

During a taper, if a patient simultaneously starts or stops any of these agents, the effective NDT dose may shift independently of the intended reduction, complicating TSH interpretation. Timing all thyroid medications on an empty stomach at least 30 to 60 minutes before food remains the standard instruction. [9]

TSH Targets and Lab Interpretation After Stopping

Understanding what a TSH result means in the weeks after stopping NDT is clinically important.

A TSH of 0.5 to 2.5 mIU/L four to six weeks after completing a full taper, with no replacement therapy, suggests significant residual thyroid function. This is most likely in patients with Hashimoto's who have partial functional reserve or in patients who were overtreated to begin with.

A TSH above 10 mIU/L with overt symptoms confirms clinical hypothyroidism and warrants prompt reintroduction of thyroid hormone, whether NDT or levothyroxine.

The reference range for TSH in most US laboratories is 0.45 to 4.5 mIU/L, though the ATA has noted that the upper limit of 4.5 mIU/L may be set too high because older individuals with subclinical hypothyroidism shift the population mean upward. [2] For patients under age 60, a TSH above 3.0 mIU/L accompanied by symptoms may justify restarting therapy even before crossing the formal laboratory threshold.

Free T4 below 0.8 ng/dL in the setting of rising TSH confirms inadequate hormone replacement and supports reintroduction.

What to Expect: A Realistic Symptom Timeline

Week 1 to 2 after last dose (abrupt stop): T3 clears first. Fatigue, mild brain fog, and increased cold sensitivity may appear by day four to seven. These symptoms are real but do not yet reflect full hypothyroidism.

Week 2 to 4: T4 levels fall progressively. TSH begins to rise. Symptoms may intensify. This is the window most patients describe as the "hardest" period.

Week 4 to 8: TSH reaches a new steady state. If the patient's thyroid produces no or minimal endogenous hormone, TSH will typically exceed 10 mIU/L by week six to eight. Overt symptoms are present.

Week 8 to 12: Without replacement, subclinical hypothyroidism transitions to overt hypothyroidism in most post-thyroidectomy patients. Lipid panels worsen (LDL rises on average 10 to 20 mg/dL), resting heart rate drops, and reflexes slow measurably.

Patients with residual thyroid function may plateau at a TSH of 3 to 8 mIU/L and remain mildly symptomatic without progressing to overt disease.